Paradoxical Enhancement of Atherosclerosis by Probucol Treatment in Apolipoprotein E-Deficient Mice.

Journal of Clinical Investigation - United States
doi 10.1172/jci119479
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

597. Therapy of Atherosclerosis in Apolipoprotein E-Deficient Mice

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice

Circulation
Cardiovascular MedicinePhysiologyCardiology
2001English

Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E-Deficient Mice

Circulation
Cardiovascular MedicinePhysiologyCardiology
2005English

Inhibition of Endoplasmic Reticulum Stress and Atherosclerosis by 2-Aminopurine in Apolipoprotein E-Deficient Mice

ISRN Pharmacology
2013English

Silence of NLRP3 Suppresses Atherosclerosis and Stabilizes Plaques in Apolipoprotein E-Deficient Mice

Mediators of Inflammation
ImmunologyCell Biology
2014English

Deficiency of Acyl CoA:cholesterol Acyltransferase 2 Prevents Atherosclerosis in Apolipoprotein E-Deficient Mice

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2003English

Proatherogenic and Antiatherogenic Effects of Probucol and Phytosterols in Apolipoprotein E Deficient Mice : Possible Mechanisms of Action

Circulation
Cardiovascular MedicinePhysiologyCardiology
1999English

Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice

Scientific Reports
Multidisciplinary
2019English

Atherosclerosis: The Apolipoprotein E-Deficient Mouse Model Revisited

Microscopy and Microanalysis
Instrumentation
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy